Press Release: The Center for Genomic Interpretation Calls upon Medical Insurers to Cover Confirmatory Testing of 23andMe Customers who are Positive for BRCA1 185delAG, BRCA1 5382insC, or BRCA2 6174delT

23andMe, Inc. recently began reporting three pathogenic variants known to increase a person’s risk for breast and ovarian cancer, among other hereditary cancers. These variants, reported by 23andMe as BRCA1 185delAG, BRCA1 5382insC, and BRCA2 6174delT, are some of the best studied and published pathogenic variants in Hereditary Breast and Ovarian Cancer syndrome. For many [...]